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ABSTRACT 
Adverse drug reactions (ADRs) are one of the major reasons for morbidity and mortality in India, but they often go undetected and under reported. 
Nevirapine (NVP) is one of the first line agents used for anti retroviral treatment (ART) of human immunodeficiency virus (HIV) infection. It is 
known to cause mild skin rash among these individuals during the first weeks of therapy, however Stevens Johnsons Syndrome (SJS) is rare. Here 
we report afifty three-year-old HIV positive individual presenting with maculopapular rash all over the body and ulcerations of the oral and genital 
mucosa following administration of NVP. He was diagnosed to have SJS. The symptoms resolved completely 2 weeks after stopping the drug. 
Causality assessment using Naranjo and the World Health Organisation (WHO) probability scale indicated a probable relationship between the 
patient’s symptoms and the use of NVP. Thus, clinicians should be vigilant to allow early detection of these problems, as the early diagnosis and 
treatment of SJS can reduce the morbidity and mortality considerably.  
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INTRODUCTION 
Nevirapine (NVP), a potent dipyridodiazepinone non-nucleoside 
reverse transcriptase inhibitor (NNRTI), was the first drug of its 
category, available in 1997, for the treatment of human 
immunodeficiency virus (HIV) infection [1, 2]. According to the 
National AIDS Control Organisation guidelines (NACO), NVP is one of 
the first line drugs used for treatment of HIV. It is used as a part of 
combination therapy for both post exposure prophylaxis as well as 
part of highly active anti retroviral therapy (HAART) regimens [3]. 
NVP binds directly to the reverse transcriptase enzyme and blocks 
RNA-dependent and DNA-dependent DNA polymerase activity, 
thereby causing disruption of the enzyme’s catalytic site [1, 2]. The 
common adverse drug reactions (ADRs) associated with NVP are 
skin rashes and hepatotoxicity. Skin rashes are usually mild and 
Stevens Johnsons Syndrome (SJS) is rarely seen in only about 0.5-1% 
cases [4]. NVP based HAART regimens have been widely prescribed 
in resource-restricted countries like India because of their efficacy, 
good tolerability, accessibility and comparatively low cost [1, 2, 4]. 
Herein, we report a case of SJS due to NVP based HAART regimen. 
CASE REPORT 
The case study below was prepared in accordance with the 
principles in the Declaration of Helsinki. Consent was taken from the 
patient on a suitably designed patient informed consent form. 
A newly HIV diagnosed fifty three-year-old male patient, on HAART 
regimen with lamivudine (3TC), stavudine (d4T) and NVP since 1 
week, presented with complaints of fever, headache, weakness, 
itching and extensive rash all over the body since 3 days. He also had 
facial and lip swelling and lesions in the oral cavity and genital 
mucosa associated with redness and pain. On examination, patient 
had fever and generalised maculopapular rashes all over the body 
which was bright red in colour, itchy and diffuse (fig. 1). Oral 
examination revealed multiple oral ulcers over the lips, labial 
mucosa, hard and soft palate, buccal mucosa and floor of the mouth. 
Haemorrhagic crusted lesions were seen on both upper and lower 
lips (fig. 2). Ulceration of the genitalia was also noted. All 
hemotological and biochemical parameters were in normal limits, 
with a CD4 count of 0.00011 cells/l (110 cells/mm3
 
). SJS was 
diagnosed based on his history and clinical presentation. NVP, 3TC 
and d4T were stopped immediately and the patient was managed 
conservatively with cold sponging and oral antihistaminic cetirizine 
10 mg once daily. There was gradual improvement in patient’s 
condition over the next 1 week and lesions completely disappeared 
after 2 weeks. Re challenge with NVP was not performed due to 
ethical constraints, but a modified HAART regimen was started that 
included efavirenz (EFV) in place of NVP. Causality assessment was 
done using Naranjo’s criteria and the World Health Organisation 
(WHO) probability scale and this case of SJS recorded a probable 
association between the reaction and drug intake (Naranjo score 6). 
 
Fig. 1: Maculopapular rash over the body 
 
 
Fig. 2: Haemorrhagic ulcerations of mucosal surface of oral 
cavity 
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SJS is an immune complex hypersensitivity reaction characterized by 
extensive necrosis and detachment of the epidermis and erosions of 
mucous membrane [3, 4]. Studies reveal that the mechanism 
involved in drug induced SJS is neither dose-independent nor 
associated with alterations in the CYP450 enzyme system but is 
more likely due to hypersensitivity reactions in which drugs act as 
antigen and induce T cell mediated immune response in genetically 
susceptible individuals. Individuals with antigens like HLA Bw44, 
HLA-B12 and HLADQB1 * 0601 appear to be more prone to develop 
SJS. Granulysin, a cationic cytolytic protein released primarily by 
cytotoxic T cells (CTLs) and natural killer (NK) cells, is considered a 
key mediator responsible for the disseminated keratinocyte death 
and tissue damage, thereby producing the unique clinical 
presentation of SJS [5]. 
SJS can be caused by various factors like infections, malignancies 
however drugs are implicated as the major causative agent [3, 6, 7]. 
Studies report that most cases of SJS in HIV patients were due to 
antibacterial sulphonamides in western countries and thiacetazone 
in Africa [6]. In our patient, the development of mucocutaneous 
lesions had a temporal relationship with administration of NVP as an 
interval of 4-28 days between initiation of drug use and on set of the 
reaction is highly suggestive of an association between the drug and 
SJS [5]. Moreover the signs and symptoms were most consistent 
with NVP induced SJS, so we believe that NVP was responsible for 
the SJS in this patient. Other drugs like 3TC and d4T can be excluded 
as there is no obvious association with SJS [2] and no reaction was 
observed when they were re challenged. Known risk factors for SJS 
include female gender, previous history of drug allergy, low body 
weight, high NVP plasma concentration and CD4 counts>0.00025 
cells/l (250 cells/mm3) in women and>0.0004 cells/l (400 
cells/mm3)in men [7]. While our patient had a low CD4cell count of 
0.00011 cells/l (110 cells/mm3), he was average build and had no 
previous history of drug allergy. Moreover, HIV-infected patients are 
at higher risk of developing SJS because of decreased anti-oxidant 
levels due to infection. 
The initial skin lesions in SJS are usually erythematous, irregularly 
shaped purpuric macules which progressively coalesce followed by 
necrosis and detachment [3-5]. It mainly involves the face, trunk and 
proximal limbs [3, 5]. Mucous membrane involvement of at least two 
sites is seen in approximately 90% of cases, before or following skin 
eruption [3, 4]. SJS is also associated with extra cutaneous symptoms 
like fever, pain, weakness etc. [3]. Our patient had red and itchy 
maculopapular rashes all over the body, painful ulcerations and 
haemorrhagic lesions involving the oral cavity and genitala along 
with extra cutaneous symptoms like fever, weakness and headache. 
Investigations usually involve a complete blood count. This may be 
normal but a significantly elevated count indicates superimposed 
infection [
In addition, the greater likelihood of using 
high doses of drugs by these patients, further predisposes them to 
SJS [7]. 
6]. In our patient the counts were normal denoting any 
underlying infection was less likely. SJS has high morbidity and is 
potentially life-threatening. Mortality rates are estimated to be 
approximately 5% [4]. Treatment includes prompt recognition and 
withdrawal of suspected drugs and hospitalization [3, 
5]. 
1. 
Management primarily involves supportive and symptomatic 
care [4]. Because of the role of immunologic and cytotoxic 
mechanisms in the development of SJS, a large number of 
immunosuppressive and anti-inflammatory therapies have been 
used to prevent the progression of the disease [3]. However, 
management in our patient involved with drawal of the offending 
agent and conservative care with oral antihistaminics as no specific 
signs of infection were identified.  
Anti retroviral treatment (ART) is becoming increasingly complex 
[2, 5]. Close monitoring and follow-up of patients placed on NVP is 
important not only to improve adherence, hence efficacy but also to 
prevent the development of severe complications such as SJS. One 
must suspect SJS, if a patient on NVP, presents with symptoms such 
as irritation of the skin and mucous membranes [5]. 
CONCLUSION  
Necessary precautions must be taken while introducing NVP in any 
HIV patients. It is necessary to keep them under strict observation 
for the first few months following the start of treatment with NVP. It 
is also important to forewarn them about such possible reactions 
and the importance of seeking medical help immediately if any skin 
reactions develop. Moreover, it may be appropriate to start NVP as 
lead dose to sensitize the immune system gradually and to avoid 
serious ADRs. This may help prevent life threatening reactions and 
at the same time may prevent non adherence to treatment. This case 
report also tends to highlight the role of genetic determination of 
individuals susceptible to such ADRs and the use of personalised 
medicine in the management of HIV. 
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